Hope in stopping melanoma from spreading: Study shows that inhibiting key protein prevents metastasis to lungs in mice

Hope in stopping melanoma from spreading: Study shows that inhibiting key protein prevents metastasis to lungs in mice
An image of Melanoma skin cancer. Credit: Courtesy of University of Utah Health Care

(Medical Xpress)—Researchers have identified a critical protein role in the metastasis of melanoma, the most serious form of skin cancer. Inhibition of the protein known as adenosine diphosphate ribosylation factor 6 (ARF6) reduces the spread of melanoma to the lungs in mice, according to a study published in the March 5 issue of Science Signaling online, suggesting that targeting ARF6 may be an effective approach to preventing melanoma metastasis.

Melanoma is the sixth most common cancer in the United States. Approximately one in 50 people will develop melanoma in their lifetime, and the number of melanoma cases diagnosed each year is increasing faster than for any other cancer. While melanoma generally starts as a single , cancer cells can spread, or metastasize, to distant sites throughout the body such as the liver, lungs, and brain.

"Metastasis is what makes melanoma lethal, but our knowledge of how melanoma spreads is limited," says Allie Grossmann, M.D., Ph.D., molecular genetic pathology fellow at the University of Utah and co-first author on the study. "By improving our understanding of the responsible for melanoma metastasis, we can better identify targeted therapies that may stop the spread of ."

Although significant progress has been made in the treatment of metastatic melanoma, currently available treatments still can't achieve long-term survivorship in most patients. Grossmann and her colleagues discovered a new molecular pathway involving ARF6 that promotes metastasis and can be inhibited by a small molecule known as SecinH3. "The surprising discovery that SecinH3 seems to inhibit the entire metastatic signaling cascade represents a potential breakthrough that may lead to improvements in the efficacy of current drug therapy. Our findings are exciting because the clinical implications extend beyond melanoma to other cancers, such as and a type of known as glioblastoma, in which invasion is also mediated by ARF6."

Based on the findings of this study and other previous studies by the same group that show the importance of ARF6 in other biological processes, Navigen Inc., a Salt Lake City-based pharmaceutical and medical device company, is investigating new ARF6 inhibitors for pre-clinical studies.

"Although SecinH3 itself is not suitable for treatment in human patients, it serves as a useful model compound for demonstrating that small-molecule inhibitors of ARF6 may have therapeutic value in melanoma," says Shannon Odelberg, Ph.D., U of U assistant professor of internal medicine and neurobiology and anatomy Navigen scientist, and a contributing author on the study. "Our findings are the first step toward developing potent therapies that may actually prevent or reduce melanoma metastasis," says Odelberg, also part of the Molecular Medicine Program at the University of Utah. "These new therapies could potentially be used in combination with current drugs to produce a more effective treatment for melanoma."


Explore further

Gene inactivation drives spread of melanoma: study

Journal information: Science Signaling

Provided by University of Utah
Citation: Hope in stopping melanoma from spreading: Study shows that inhibiting key protein prevents metastasis to lungs in mice (2013, March 5) retrieved 24 August 2019 from https://medicalxpress.com/news/2013-03-melanoma-inhibiting-key-protein-metastasis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more